Radiopharmaceutical developer Ground Fluor Pharmaceuticals has received a $728,000 phase II Small Business Innovation Research (SBIR) grant.  The grant will be used to expand research and product development of the company’s proprietary chemistry for the production of F-18 fluorodopa, a PET imaging agent intended for diagnosing and managing brain tumors (such as astrocytomas and gliomas) and Parkinson’s disease.  {read more here}